TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03256227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Supported Prolonged Exposure
Description: The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prolonged Exposure
Description: Standard Prolonged Exposure for PTSD as delivered in routine VA care.
Study: NCT01470898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bispectral index monitoring
Description: A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bispectral index monitoring
Description: A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
Study: NCT00032227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Carpal Tunnel Release for Mild or Moderate CTS
Description: Either open or endoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Carpal Tunnel Release for Mild or Moderate CTS
Description: Either open or endoscopic surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Nerve Imaging for CTS
Description: New diagnostic test for CTS to directly image the median nerve

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Nerve Imaging for CTS
Description: New diagnostic test for CTS to directly image the median nerve
Study: NCT00769496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 77-1931
Description: Lanthanum Carbonate (BAY 77-1931)
Study: NCT00024154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01006954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdose GnRh
Description: Microflare protocol in poor responders for IVF/ICSI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flare up
Description: Flare up protocol in poor responders for IVF/ICSI
Study: NCT00549497

Intervention type: DRUG
Group type: OTHER
Intervention: GW870086X
Study: NCT00893217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: 250 mcg
Study: NCT03687619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP
Description: Interventions (from top to down) related to the development of fine-motor skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conductive Education
Description: Interventions (from down to top) related to the development of fine-motor skills
Study: NCT03563794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII+Vildagliptin
Description: Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII(insulin Lispro)
Description: T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
Study: NCT06642779

Intervention type: DIAGNOSTIC_TEST
Intervention: UIVA / DCIVA
Description: Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.

Intervention type: DIAGNOSTIC_TEST
Intervention: UIVA / DCIVA
Description: Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.

Intervention type: DIAGNOSTIC_TEST
Intervention: UNVA / DCNVA
Description: Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.

Intervention type: DIAGNOSTIC_TEST
Intervention: UNVA / DCNVA
Description: Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Manifest Refraction
Description: Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.

Intervention type: DIAGNOSTIC_TEST
Intervention: Manifest Refraction
Description: Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
Study: NCT01531491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rebreathing tube
Description: 750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No rebreathing tube (Nothing)
Description: 750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
Study: NCT04013581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZD group
Description: Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT-2 group
Description: Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
Study: NCT03532555

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate
Description: Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No supplemental zinc
Description: Infants will receive standard of care, which is currently no supplemental zinc
Study: NCT01444521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan and cisplatin
Description: irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles.
Study: NCT01988012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 162 milligram (mg) administered subcutaneously once weekly for 24 weeks
Study: NCT02067156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study: NCT00893217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: 500 mcg
Study: NCT04027361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine Extended Release (ER) Tablet 20 mg
Description: A single 20 mg dose of amphetamine ER Tablet, orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amphetamine Extended Release (ER) Tablet 20 mg
Description: A single 20 mg dose of amphetamine ER Tablet, orally administered
Study: NCT02813499

Intervention type: OTHER
Intervention: CARE Rule
Description: Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
Study: NCT02646553

Intervention type: OTHER
Intervention: Children refered to the obesity clinic
Description: Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
Study: NCT01556841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax®
Description: Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only.
Study: NCT02814760

Intervention type: OTHER
Intervention: training of emergency professionals to acute stroke management
Description: The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization).
Study: NCT03128203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, intranasally administrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline, intranasally administrated
Study: NCT02488772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care as decided by treating emergency physician

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear Plugs
Study: NCT02331940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handihaler
Description: Inhalation via the HandiHaler once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Inhalation via the Respimat once daily
Study: NCT00002956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
Study: NCT02123966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT00593164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling with ThermoSuit with Magnesium Sulfate Infusion
Description: Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling with ThermoSuit with Normal Saline Infusion
Description: Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
Study: NCT02883322

Intervention type: OTHER
Intervention: Cross cultural adaptation of patient reported outcomes (PRO)
Description: Process used to adapt a questionnaire from one cultural setting to another

Intervention type: OTHER
Intervention: Cross cultural adaptation of patient reported outcomes (PRO)
Description: Process used to adapt a questionnaire from one cultural setting to another

Intervention type: OTHER
Intervention: Cross cultural adaptation of patient reported outcomes (PRO)
Description: Process used to adapt a questionnaire from one cultural setting to another

Intervention type: OTHER
Intervention: Cross cultural adaptation of patient reported outcomes (PRO)
Description: Process used to adapt a questionnaire from one cultural setting to another
Study: NCT01747161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulin toxin
Description: 50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological water
Description: 3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
Study: NCT01013675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in egg (influvac ®)
Study: NCT01445639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: as placebo
Study: NCT03679130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training
Description: EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational counseling supported by health technology
Description: MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
Study: NCT03756389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010
Description: Safety and efficacy of BMX-010 in topical treatment of rosacea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010
Description: Safety and efficacy of BMX-010 in topical treatment of rosacea.
Study: NCT00839228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: 100mg o bd for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet bd for 3 months
Study: NCT01824446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled SPD602 (FBS0701, SSP-004184)
Description: A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
Study: NCT01033643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Description: Participants were administered 0.25 mg tablet, orally for a total daily dose according to randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-3614
Description: Participants were administered dose matched placebo tablets according to randomization.
Study: NCT02442414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5209
Description: Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
Study: NCT01456663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study: NCT00536666

Intervention type: DRUG
Group type: OTHER
Intervention: Iron oligosaccharide
Study: NCT04559464

Intervention type: DEVICE
Group type: OTHER
Intervention: AeriSeal
Description: The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
Study: NCT03892850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse prescription
Description: Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription
Description: Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
Study: NCT03927365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation from a salt particle inhaler with or without content
Description: Inhalation from inhaler with (active) or without (placebo) content
Study: NCT04484909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT00027612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02091063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Description: All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
Study: NCT03449459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral probiotics
Description: Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time.
Study: NCT04559464

Intervention type: DEVICE
Group type: OTHER
Intervention: Zephyr Valves
Description: The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
Study: NCT04854317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gastroplasty
Description: Endoscopic Gastroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gastroplasty
Description: Endoscopic Gastroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic gastroplasty
Description: Endoscopic Gastroplasty